Andera Partners

Andera Partners, founded in 2001 and based in Paris, France, is a private equity firm that specializes in investing in growth-stage companies. The firm focuses on a diverse range of sectors, including sustainable energy, transportation and logistics, agribusiness, business-to-business and business-to-consumer services, building and construction, cosmetics, distribution, information technology and software, media, medical technology, real estate, therapeutic products, and tourism. Andera Partners employs a strategy centered on buyouts, aiming to support companies with innovative solutions and sustainable growth potential. With a commitment to fostering long-term performance, the firm leverages its expertise and experience to anticipate market trends and cultivate valuable relationships with its portfolio companies.

The Bioclinic Group is a medical company that operates medical analysis laboratories. It was founded in 1995 and is based in Paris, France.

GLOBE Groupe is a Paris-based agency that specializes in advertising services and strategic marketing. The company offers a range of services including communication strategy, talent castings, recruitment, training, payroll, and various logistical solutions such as storage, dispatch, and cold-chain logistics. GLOBE focuses on shopper marketing, implementing experiences that convert consumers into shoppers while assessing campaign effectiveness through established performance indicators. They utilize a comprehensive methodology to evaluate the impact of their marketing efforts, ensuring that all operations are tracked through a secure extranet platform, myGLOBE, which provides real-time updates and data confidentiality. The company serves diverse sectors including consumer goods, media, and retail, aiming to enhance brands' commercial transformation and drive sales growth for its clients.

Allodiagnostic SAS, based in Paris, France, specializes in providing essential real estate diagnostics, including assessments for termites, electrical systems, and energy performance. Founded in 2001, the company caters to private individuals during the sale or rental of properties. It serves as a key resource for both consumers and real estate professionals, offering tailored solutions to meet various diagnostic requirements. As of July 2017, Allodiagnostic operates as a subsidiary of Edmond de Rothschild (France).

Finsecur S.A. is a French company based in Paris that specializes in the design, manufacture, and maintenance of fire-detection systems. Established in 2000, it offers a range of products including detectors, control panels, and accessories, as well as comprehensive fire alarm systems such as home fire detectors, extinguishing systems, and smoke clearing panels. Additionally, the company provides technical alarms for monitoring defects and anomalies in installations, including alarm panels and sprinkler system monitoring. Finsecur's products cater to various sectors, including clean rooms, telecoms, airports, and military industries. The company has been recognized for its innovation and growth, having received the BPI label Excellence, which connects it with a network of leading French companies in technology.

A2iA S.A. specializes in the development of advanced software tools for handwritten and machine-printed text recognition, information extraction, and intelligent document classification. Its product offerings include a2ia Mobility, which supports various workflows such as mobile remote deposit capture and ID verification; a2ia mNote, designed for offline conversion of handwritten notes into digital formats; and a2ia DocumentReader, which extracts data from both structured and unstructured documents. Additional tools include a2ia TextReader for transcribing printed and cursive handwriting, a2ia CheckReader for automated data capture from payment documents, and a2ia FieldReader for extracting information from forms. A2iA caters to a diverse clientele across sectors such as banking, fintech, telecom, healthcare, and government, serving markets in Europe, North America, Latin America, the Middle East, Africa, India, and the Asia Pacific. Founded in 1991 and headquartered in Paris, with an office in New York, A2iA operates as a subsidiary of Mitek Systems, Inc.

EOS imaging is a medical company revolutionizing the treatment continuum for the most common osteoarticular conditions (hip, knee and spine) and associated orthopedic surgeries. Its EOS® 2D/3D imaging system is specifically adapted to the needs of orthopedic surgeons and radiologists. This personalized imaging tool gives a precise 3D image of the patient's skeleton in the upright position that can be used to inform all aspects of care. The Company has obtained authorization to market the system in 48 countries. The Company is based in Paris, with a subsidiary in the United States in Cambridge, Massachusetts, as well as offices in Montreal (Canada) and Germany.

Cellectis S.A. is a clinical-stage biotechnological company headquartered in Paris, France, focused on developing immuno-oncology products utilizing gene-edited T-cells that express chimeric antigen receptors to target cancer cells. The company's primary portfolio includes several allogeneic T-cell product candidates such as UCART19, designed for treating CD19-expressing hematologic malignancies, and UCART123 for acute myeloid leukemia. Additional candidates include ALLO-501 for relapsed/refractory diffuse large B-cell lymphoma, UCART22 for B-cell acute lymphoblastic leukemia, and products targeting multiple myeloma, such as UCARTCS1 and ALLO-715. In addition to its therapeutic developments, Cellectis also produces high oleic soybean oil and other agricultural products. The company has established strategic partnerships with various institutions, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to innovate in the field of gene editing and immunotherapy.

Cellectis S.A. is a clinical-stage biotechnological company headquartered in Paris, France, focused on developing immuno-oncology products utilizing gene-edited T-cells that express chimeric antigen receptors to target cancer cells. The company's primary portfolio includes several allogeneic T-cell product candidates such as UCART19, designed for treating CD19-expressing hematologic malignancies, and UCART123 for acute myeloid leukemia. Additional candidates include ALLO-501 for relapsed/refractory diffuse large B-cell lymphoma, UCART22 for B-cell acute lymphoblastic leukemia, and products targeting multiple myeloma, such as UCARTCS1 and ALLO-715. In addition to its therapeutic developments, Cellectis also produces high oleic soybean oil and other agricultural products. The company has established strategic partnerships with various institutions, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to innovate in the field of gene editing and immunotherapy.